American Well (NYSE:AMWL) Director Deborah C. Jackson Sells 4,531 Shares

Key Points

• Director Deborah Jackson of American Well sold 4,531 shares at an average price of $6.56, lowering her stake in the company by 10.38%.
• American Well reported a quarterly EPS of ($1.24), surpassing analysts' expectations of ($1.84) and generating $70.90 million in revenue.
• Analysts have adjusted their price targets for AMWL, with Wells Fargo lowering it from $15.00 to $12.00 while maintaining an "overweight" rating.

American Well Corporation (NYSE:AMWL - Get Free Report) Director Deborah C. Jackson sold 4,531 shares of the business's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $6.56, for a total value of $29,723.36. Following the transaction, the director owned 39,132 shares in the company, valued at $256,705.92. This represents a 10.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

American Well Trading Down 0.8%

NYSE:AMWL traded down $0.06 during mid-day trading on Friday, hitting $6.50. The company's stock had a trading volume of 93,715 shares, compared to its average volume of 57,507. The stock has a fifty day moving average of $7.34 and a 200-day moving average of $7.39. American Well Corporation has a fifty-two week low of $6.09 and a fifty-two week high of $12.95. The company has a market capitalization of $104.89 million, a price-to-earnings ratio of -0.80 and a beta of 1.27.

American Well (NYSE:AMWL - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.84) by $0.60. American Well had a negative net margin of 46.15% and a negative return on equity of 41.99%. The company had revenue of $70.90 million during the quarter, compared to analysts' expectations of $63.87 million. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts anticipate that American Well Corporation will post -9.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On American Well

Hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp raised its position in American Well by 7.4% during the fourth quarter. Northern Trust Corp now owns 29,021 shares of the company's stock valued at $210,000 after purchasing an additional 1,992 shares in the last quarter. Jane Street Group LLC increased its stake in shares of American Well by 21.9% in the 4th quarter. Jane Street Group LLC now owns 19,260 shares of the company's stock valued at $140,000 after purchasing an additional 3,462 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of American Well during the 4th quarter worth $76,000. Two Sigma Advisers LP lifted its position in shares of American Well by 102.7% during the 4th quarter. Two Sigma Advisers LP now owns 41,045 shares of the company's stock worth $298,000 after buying an additional 20,800 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in American Well by 12.3% in the fourth quarter. Two Sigma Investments LP now owns 19,216 shares of the company's stock valued at $139,000 after buying an additional 2,102 shares in the last quarter. 56.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wells Fargo & Company reduced their price target on shares of American Well from $15.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.17.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.